Skip menus, go to main page content

To Our Shareholders
and Investors

Top
To Our Shareholders and Investors

IR News

August 26, 2026

R & D

SAKIGAKE Pharmaceutical Product (Pioneering Drug) Designation Granted to NS-035 for the Treatment of Fukuyama Congenital Muscular Dystrophy
August 25, 2026

Corporate

CAP-1002 (deramiocel): Notice Regarding Extension of the PDUFA Date
August 25, 2026

R & D

Regulatory Update on RGX-121 for MPS II
August 19, 2026

Management & Finance

Notice Regarding Completion of Disposal of Treasury Stock as Restricted Stock Compensation

Upcoming Events

August 06, 2026
FY2026 1st Qtr results announcement and IR meeting
May 15, 2026
Annual results announcement and IR meeting （Q4/FY2025）
March 02, 2026
R&D Meeting
February 09, 2026
IR Meeting (Q3/FY2025)
February 09, 2026
FY2025 3rd Qtr Results Announcement

Financial/Capital Strategy

Management Policy and Plan

Business/Financial Information

IR Library

Sustainability Management

Stock and Shareholder Information

To Our Individual Investors

IR e-mail

Subscribe (only 1 minute required) to receive the latest news by e-mail.

Most Viewed Pages

Aug 1-31, 2026

All Japanese Listed Companies' Website Ranking

Gomez
IR Site Ranking Silver 2025

Daiwa Investor Relations Co.Ltd. 2025 Internet IR Award

Related Link

Nippon Shinyaku’s DNA

Research & Development

Top
To Our Shareholders and Investors